About Us
Management
Board of Directors
Job Opportunities
Pipeline
AGB101 for MCI due to AD
About MCI due to Alzheimer’s Disease
Novel GABA(A) α5 Discovery Program
The Science
Newsroom
Publications
Investor Relations
Patient Resources
MCI due to Alzheimer’s Disease
Autism
Schizophrenia
Toggle navigation
Check back often to
find the latest news on AgeneBio and our pipeline of multiple candidates
.
« back to Press Releases
April 21, 2021
Richard Mohs, AgeneBio VP for Clinical Development, Presents at 2021 NIH Alzheimer Disease Summit
AGB101 to Slow the Progression of MCI in Alzheimer’s Disease
Email Alerts
Stay up to date on the latest AgeneBio news.
Register Now
